Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2020-03-16 Regulatory Filings
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Wpływ koronawirusa na działalność Emitenta i jego Grupy Kapitałowej - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is very short (842 characters) and discusses the potential impact of the COVID-19 pandemic on the Issuer's operations and financial results. It explicitly states that if new circumstances arise that significantly impact financial results, they will be made public in current reports via the ESPI system. This structure—a brief announcement about a potential future impact or disclosure requirement, rather than the detailed financial report itself—suggests it is a general regulatory disclosure. Since it doesn't fit specific categories like Earnings Release (ER), Interim Report (IR), or a specific transaction, the most appropriate fallback category for a general regulatory announcement not covered elsewhere is Regulatory Filings (RNS).
2020-03-16 Polish
PHARMENA Projekty uchwał na NWZ w dniu 07 04 2020
AGM Information Classification · 99% confidence The document text explicitly mentions 'Projekty uchwał Nadzwyczajnego Walnego Zgromadzenia' (Draft resolutions of the Extraordinary General Meeting) and details specific resolutions passed by this meeting ('Nadzwyczajne Walne Zgromadzenie'). This content directly relates to the proceedings and outcomes of a shareholder meeting. Although it contains details about loan approvals (which might touch upon financing/CAP), the primary context is the meeting itself and its resolutions. The closest fit among the provided definitions is 'AGM Information' (AGM-R), as an Extraordinary General Meeting (EGM) is functionally similar to an AGM in terms of shareholder governance documentation, and the document lists the resolutions passed there. It is not a declaration of voting results (DVA), but the resolutions themselves.
2020-02-28 Polish
PHARMENA_Ogłoszenie o zwołaniu NWZ w dniu 07 04 2020
AGM Information Classification · 99% confidence The document is titled "Ogłoszenie o zwołaniu Nadzwyczajnego Walnego Zgromadzenia Spółki..." which translates to "Announcement of the convening of an Extraordinary General Meeting of the Company...". It details the date, time, location, and the agenda (Porządek obrad) for this meeting, along with detailed procedures for shareholder participation, voting by proxy, and submitting proposals. This content directly relates to the formal process of calling and conducting a General Meeting of Shareholders. The most appropriate classification among the provided options is AGM-R (AGM Information), as it is the official notice and material related to the Annual/Extraordinary General Meeting.
2020-02-28 Polish
Zwołanie Nadzwyczajnego Walnego Zgromadzenia spółki Pharmena S.A. - Content (PL)
AGM Information Classification · 95% confidence The document text is in Polish and announces the convening ('zwołaniu') of an Extraordinary General Meeting ('Nadzwyczajnego Walnego Zgromadzenia') scheduled for April 7, 2020. It explicitly states that the Management Board is enclosing ('w załączeniu przekazuje') the announcement along with draft resolutions ('projektami uchwał'). This content—announcing a shareholder meeting and providing related materials—is characteristic of materials prepared for or related to a General Meeting. Since it is an announcement about convening the meeting, it aligns best with the 'AGM Information' category, even though it is an Extraordinary General Meeting (EGM), as there is no specific EGM code, and AGM-R covers general meeting materials.
2020-02-28 Polish
Dalsze etapy komercjalizacji leku 1-MNA (TRIA-662) w PAH - Content (PL)
Regulatory Filings Classification · 99% confidence The document is a formal announcement by the Management Board (Zarząd) of PHARMENA S.A. referencing previous regulatory reports (raport bieżący nr 3/2020 and nr 43/2019) via the ESPI system. It details strategic decisions regarding the commercialization path for drug candidate 1-MNA (TRIA-662) for NASH and PAH indications, including prioritizing discussions with the pharmaceutical industry. The final paragraph explicitly states that the information is being disclosed because the successful commercialization of 1-MNA could significantly impact the Issuer's financial results and market valuation. This structure—a formal update on strategic business/drug development milestones that have material financial implications, issued outside of standard periodic reports (10-K, IR)—is characteristic of a general regulatory disclosure or an announcement related to corporate activity that doesn't fit a more specific category like M&A (TAR) or Financing (CAP). Since it is a material update concerning the company's core operations and future value, and it references prior regulatory filings, it fits best as a general Regulatory Filing (RNS) or potentially a Management Report (MDA) if it were a more detailed explanation of results, but given the context of updating on commercialization strategy following prior reports, RNS is the most appropriate general disclosure category.
2020-02-22 Polish
Planowane spotkanie Pre-IND Meeting z przedstawicielami FDA w ramach rozwoju projektu leku 1-MNA we wskazaniu NASH. - Content (PL)
Capital/Financing Update Classification · 95% confidence The document text discusses strategic decisions regarding clinical trials for a drug (1-MNA) targeting NASH, including plans for FDA consultation (Pre-IND Meeting) and securing financing (loans from major shareholders) to cover associated costs. This content relates to the company's ongoing development, financing, and regulatory strategy concerning a specific project. It is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a formal announcement of a dividend (DIV) or management change (MANG). It details financing activities (loans from shareholders) related to capital expenditure for regulatory preparation, which strongly aligns with the 'Capital/Financing Update' (CAP) category, as it describes securing funds for a specific corporate activity. While it mentions FDA consultation, it is primarily a disclosure about securing necessary capital for that step, rather than just a general regulatory filing (RNS) or a legal proceeding report (LTR). The financing aspect is central to the disclosure. Given the focus on securing 1 million PLN in loans from key shareholders to fund FDA documentation and consultation costs for a drug development project, the most appropriate classification is Capital/Financing Update (CAP).
2020-02-14 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.